Expectant Management of Prostate Cancer With Curative Intent: An Update of The Johns Hopkins Experience
We updated our experience with a strategy of expectant treatment for men with stage T1c prostate cancer and evaluated predictors of disease intervention.
Materials and Methods:
A total of 407 men with a median age of 65.7 years (range 45.8 to 81.5) with stage T1c (99.8%) or T2a (0.2%) prostate cancer suspected of harboring small volume prostate cancer based on needle biopsy findings and prostate specific antigen density have been followed in a prospective, longitudinal surveillance program with a median followup of 2.8 years (range 0.4 to 12.5). A recommendation for treatment was made if disease progression was suggested by unfavorable followup needle biopsy findings (Gleason pattern 4 or 5, greater than 2 biopsy cores with cancer or greater than 50% involvement of any core with cancer). Cox proportional hazards regression was used to evaluate the affect of multiple covariates on the outcome of curative intervention.
Of 407 men 239 (59%) men remained on active surveillance at a median followup of 3.4 years (range 0.43 to 12.5), 103 (25%) underwent curative intervention at a median of 2.2 years after diagnosis (range 0.96 to 7.39) and 65 (16%) were either lost to followup (12), withdrew from the program (45), or died of causes other than prostate cancer (8). Older age at diagnosis (p = 0.011) and an earlier date of diagnosis (p = 0.001) were significantly associated with curative intervention.
Recognizing that over treatment of prostate cancer is prevalent, especially among elderly patients, a program of careful selection and monitoring of older men who are likely to harbor small volume, low grade disease may be a rational alternative to the active treatment of all.
- 1 : Lead times and overdetection due to prostate specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst2003; 95: 868. Google Scholar
- 2 : The changing face of prostate cancer. J Clin Oncol2005; 23: 8146. Google Scholar
- 3 : Prognostic markers under watchful waiting and radical prostatectomy. Hematol Oncol Clin North Am2006; 20: 845. Google Scholar
- 4 : Expectant management of stage T1c prostate cancer with curative intent: preliminary results. J Urol2002; 167: 1231. Link, Google Scholar
- 5 : Pathologic and clinical findings to predict tumor extent of non-palpable (stage T1c) prostate cancer. JAMA1994; 271: 368. Google Scholar
- 6 : Pathological outcomes are similar for men in an expectant management program undergoing delayed surgical intervention compared to those undergoing immediate intervention. J Natl Cancer Inst2006; 98: 355. Google Scholar
- 7 : An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol2004; 171: 1520. Link, Google Scholar
- 8 : Active surveillance for prostate cancer: for whom?. J Clin Oncol2005; 23: 8165. Google Scholar
- 9 : Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort. BJU Int2004; 93: 510. Google Scholar
- 10 : Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol2007; 51: 1244. Google Scholar
- 11 : Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate specific antigen era. J Clin Oncol2003; 21: 4001. Google Scholar
- 12 : PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for Prostate cancer, Sweden section. Int J Cancer2006; 120: 170. Google Scholar
- 13 : Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA2006; 296: 2683. Google Scholar
- 14 : Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol2003; 170: 1792. Link, Google Scholar
- 15 : Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance. J Urol2007; 177: 907. Link, Google Scholar